BIOTRONIK Announces Improved Patient Outcomes with Innovative “Combination Therapy” for Peripheral Artery Disease
Treatment Combining Passeo-18 Lux Drug-Coated Balloon with Pulsar-18 Stent Led to Excellent Patency and Safety
NEW YORK, US, and BUELACH, Switzerland, November 20, 2015 – BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, has presented the 24-month results from the DEBAS clinical trial at the VEITH symposium. DEBAS is the first investigator-initiated trial to demonstrate the efficacy and safety of a novel combination therapy for peripheral artery disease (PAD) using Passeo-18 Lux drug-coated balloon (DCB) and Pulsar-18 self-expanding stent (SES) to treat peripheral artery disease in a complex patient population.“BIOTRONIK’s DCB as well as SES have been proven to work as individual treatments for superficial artery disease. However, each approach has its respective limitations in certain vessel morphologies and clinical situations,” stated DEBAS principal investigator Dr. Patrice Mwipatayi, Royal Perth Hospital, Perth, Australia. “The results of DEBAS indicate that a hybrid approach combining Passeo-18 Lux with the thin-strut stent, Pulsar-18 may overcome some of these limitations and improve patients’ clinical outcomes, especially for the long and complex lesions seen in this trial.”A total of 65 patients were enrolled in the prospective, multicenter, investigator-initiated DEBAS registry, with 24-month data available for 51 patients. More than half of the patients were treated for long, complex TASC D lesions, indicative of an advanced disease state. All patients were treated with the Pulsar-18 stent followed by Passeo-18 Lux DCB. The primary endpoint was primary patency at 12 months with follow-up to 24 months. At 12 months, primary patency was very high at 92.2 percent, sustained at 88.2 percent at 24 months. Major amputation was 1.96 percent at 24 months, confirming the safety of combination therapy with Passeo-18 Lux and Pulsar-18.“Pulsar-18’s thin strut design makes this stent uniquely suited for adjunctive therapy with DCB, as thinner struts decrease the distance between the DCB’s coating and the vessel wall. A low metal-to-artery ratio guarantees that the drug can be delivered to the vessel wall following stent implantation,” explained Dr. Mwipatayi. “Additionally, Pulsar-18’s thin struts may have a ’scoring effect’ on the lesion when the Passeo-18 Lux is inflated within the stent, potentially reducing barotrauma, or injury caused by inflation of a DCB. These factors might improve drug uptake and lead to the outstanding primary patency seen in this trial.”“Passeo-18 Lux and Pulsar-18 represent key technologies in the BIOTRONIK peripheral portfolio. They have a documented history of clinical success when used as individual treatment options, and the highly encouraging results of DEBAS show that combination therapy with both can achieve even better clinical performance,” commented Dr. Alexander Uhl, BIOTRONIK Vice President Marketing, Vascular Intervention. “BIOTRONIK has established a rigorous clinical program to more fully investigate combination therapy as an alternative to existing drug-eluting approaches.
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.